Kosmos Energy Ltd. Common Shares (DE) vs TG Therapeutics Inc — how do they compare? Kosmos Energy Ltd. Common Shares (DE) trades at $2.71 (market cap $1.66B), while TG Therapeutics Inc trades at $54.41 (market cap $8.32B). The key difference: TG Therapeutics Inc is far larger — about 5× Kosmos Energy Ltd. Common Shares (DE)'s market cap, and Kosmos Energy Ltd. Common Shares (DE) is more actively traded (7,535,344 versus 1,001,204). Which is the better fit depends on your goals — on Pluang, investors hold Kosmos Energy Ltd. Common Shares (DE) for 0 Days and TG Therapeutics Inc for 16 Days on average.
| KOS | TGTX | |
|---|---|---|
Market Cap | $1.66B | $8.32B |
Volume | 7,535,344 | 1,001,204 |
Sector | Energy | Health |
52-Week High | $3.27 | $59.06 |
52-Week Low | $0.87 | $26.94 |
Typical Hold Time | 0 Days | 16 Days |
Enterprise Value | $4.30B | $8.52B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TG Therapeutics trades at $54.34, down 1.68% today, with a bullish technical outlook supported by moving averages. The company shows strong profitability with 55.22% net income margin and 100.28% ROE, though recent quarters saw EPS misses. Revenue guidance for 2026 is raised to $950M for BRIUMVI, with institutional buying interest from major banks. A shareholder investigation by Kuehn Law presents legal overhang.
Outlook remains positive given analyst consensus target of $80.50 (48% upside) and buyout speculation. Key risks include ongoing legal scrutiny and reliance on BRIUMVI's market share growth. The stock offers growth potential but requires monitoring of legal developments and competitive pressures in the MS treatment space.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Kosmos Energy Ltd. is a deepwater oil and gas exploration and production company with operations offshore Ghana, Equatorial Guinea, Mauritania, and Senegal in West Africa.
Read more on KOS →TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →